Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ovol2 promoter mutations in mice and human illuminate species-specific phenotypic divergence

SS. Sunny, J. Lachova, P. Kasparek, M. Palkova, F. Spoutil, J. Prochazka, R. Sedlacek, P. Liskova, Z. Kozmik

. 2024 ; 33 (6) : 491-500. [pub] 20240228

Language English Country England, Great Britain

Document type Journal Article

Grant support
21-27364S Czech Science Foundation
LM2018126 Czech Center for Phenogenomics Infrastructure

Pathogenic variants in the highly conserved OVOL2 promoter region cause posterior polymorphous corneal dystrophy (PPCD) 1 by inducing an ectopic expression of the endothelial OVOL2 mRNA. Here we produced an allelic series of Ovol2 promoter mutations in the mouse model including the heterozygous c.-307T>C variant (RefSeq NM_021220.4) causing PPCD1 in humans. Despite the high evolutionary conservation of the Ovol2 promoter, only some alterations of its sequence had phenotypic consequences in mice. Four independent sequence variants in the distal part of the Ovol2 promoter had no significant effect on endothelial Ovol2 mRNA level or caused any ocular phenotype. In contrast, the mutation c.-307T>C resulted in increased Ovol2 expression in the corneal endothelium. However, only a small fraction of adult mice c.-307T>C heterozygotes developed ocular phenotypes such as irido-corneal adhesions, and corneal opacity. Interestingly, phenotypic penetrance was increased at embryonic stages. Notably, c.-307T>C mutation is located next to the Ovol1/Ovol2 transcription factor binding site. Mice carrying an allele with a deletion encompassing the Ovol2 binding site c.-307_-320del showed significant Ovol2 gene upregulation in the cornea endothelium and exhibited phenotypes similar to the c.-307T>C mutation. In conclusion, although the mutations c.-307T>C and -307_-320del lead to a comparably strong increase in endothelial Ovol2 expression as seen in PPCD1 patients, endothelial dystrophy was not observed in the mouse model, implicating species-specific differences in endothelial cell biology. Nonetheless, the emergence of dominant ocular phenotypes associated with Ovol2 promoter variants in mice implies a potential role of this gene in eye development and disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007039
003      
CZ-PrNML
005      
20240423155656.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/hmg/ddad195 $2 doi
035    __
$a (PubMed)37971355
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sunny, Sweetu Susan $u Laboratory of Transcriptional Regulation, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague 4, Prague, Czech Republic $1 https://orcid.org/0009000867593206
245    10
$a Ovol2 promoter mutations in mice and human illuminate species-specific phenotypic divergence / $c SS. Sunny, J. Lachova, P. Kasparek, M. Palkova, F. Spoutil, J. Prochazka, R. Sedlacek, P. Liskova, Z. Kozmik
520    9_
$a Pathogenic variants in the highly conserved OVOL2 promoter region cause posterior polymorphous corneal dystrophy (PPCD) 1 by inducing an ectopic expression of the endothelial OVOL2 mRNA. Here we produced an allelic series of Ovol2 promoter mutations in the mouse model including the heterozygous c.-307T>C variant (RefSeq NM_021220.4) causing PPCD1 in humans. Despite the high evolutionary conservation of the Ovol2 promoter, only some alterations of its sequence had phenotypic consequences in mice. Four independent sequence variants in the distal part of the Ovol2 promoter had no significant effect on endothelial Ovol2 mRNA level or caused any ocular phenotype. In contrast, the mutation c.-307T>C resulted in increased Ovol2 expression in the corneal endothelium. However, only a small fraction of adult mice c.-307T>C heterozygotes developed ocular phenotypes such as irido-corneal adhesions, and corneal opacity. Interestingly, phenotypic penetrance was increased at embryonic stages. Notably, c.-307T>C mutation is located next to the Ovol1/Ovol2 transcription factor binding site. Mice carrying an allele with a deletion encompassing the Ovol2 binding site c.-307_-320del showed significant Ovol2 gene upregulation in the cornea endothelium and exhibited phenotypes similar to the c.-307T>C mutation. In conclusion, although the mutations c.-307T>C and -307_-320del lead to a comparably strong increase in endothelial Ovol2 expression as seen in PPCD1 patients, endothelial dystrophy was not observed in the mouse model, implicating species-specific differences in endothelial cell biology. Nonetheless, the emergence of dominant ocular phenotypes associated with Ovol2 promoter variants in mice implies a potential role of this gene in eye development and disease.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a fenotyp $7 D010641
650    12
$a dědičné dystrofie rohovky $x genetika $7 D003317
650    _2
$a rohovkový endotel $7 D004728
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a messenger RNA $7 D012333
650    _2
$a transkripční faktory $x genetika $7 D014157
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lachova, Jitka $u Laboratory of Transcriptional Regulation, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague 4, Prague, Czech Republic
700    1_
$a Kasparek, Petr $u Program in Craniofacial Biology and Department of Orofacial Sciences, University of California, 513 Parnassus Avenue, CA 94158, San Francisco, United States
700    1_
$a Palkova, Marcela $u Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prumyslová 595, 252 50, Vestec, Czech Republic
700    1_
$a Spoutil, Frantisek $u Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prumyslová 595, 252 50, Vestec, Czech Republic
700    1_
$a Prochazka, Jan $u Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prumyslová 595, 252 50, Vestec, Czech Republic
700    1_
$a Sedlacek, Radislav $u Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prumyslová 595, 252 50, Vestec, Czech Republic
700    1_
$a Liskova, Petra $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 2, 121 08, Prague 2, Prague Czech Republic $u Department of Ophthalmology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Prague, Czech Republic
700    1_
$a Kozmik, Zbynek $u Laboratory of Transcriptional Regulation, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague 4, Prague, Czech Republic
773    0_
$w MED00002077 $t Human molecular genetics $x 1460-2083 $g Roč. 33, č. 6 (2024), s. 491-500
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37971355 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155652 $b ABA008
999    __
$a ok $b bmc $g 2081192 $s 1216806
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 33 $c 6 $d 491-500 $e 20240228 $i 1460-2083 $m Human molecular genetics $n Hum Mol Genet $x MED00002077
GRA    __
$a 21-27364S $p Czech Science Foundation
GRA    __
$a LM2018126 $p Czech Center for Phenogenomics Infrastructure
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...